IDH-mutant astrocytoma with EGFR amplification - Genomic profiling in four cases and review of literature

Melissa Umphlett, Khawaja Hasan Bilal, Michael L. Martini, Abigail K. Suwala, Sadhna Ahuja, Omid Rashidipour, Isabelle Germano, Matija Snuderl, Peter Morgenstern, Nadejda M. Tsankova

Research output: Contribution to journalArticlepeer-review

Abstract

IDH-mutant astrocytomas carry significantly better prognosis compared to their IDH-wildtype grade 4 (glioblastoma) counterpart. Several molecular diagnostic markers have emerged in the 2021 CNS WHO classification, with powerful prognostic implications to consider when classifying diffuse IDH-mutant astrocytomas.1-3 EGFR amplification status, associated with aggressive glioma behavior4 and now regarded as a molecular feature of glioblastoma, is not currently a diagnostic consideration in IDH-mutant astrocytomas.1 Although uncommon, IDH-mutant astrocytomas with EGFR amplification exist in large published datasets but their relevance has been underemphasized and remains poorly understood.

Original languageEnglish
Article numbervdac067
JournalNeuro-Oncology Advances
Volume4
Issue number1
DOIs
StatePublished - 1 Jan 2022

Fingerprint

Dive into the research topics of 'IDH-mutant astrocytoma with EGFR amplification - Genomic profiling in four cases and review of literature'. Together they form a unique fingerprint.

Cite this